Despite projections implying that the clinical use of aducanumab (Aduhelm; Biogen), the first drug approved for the treatment of Alzheimer disease (AD), would be widespread by this point, financial reports have indicated that the clinical use of the therapy is far below expectations.

reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.

Researchers looking for a pre-approved drug that can be reused to treat Alzheimer’s disease have found promising signs of efficacy in a 50-year-old generic drug commonly used as a diuretic.

A generic drug used widely to treat swelling associated with hypertension and heart failure showed hints in early research that it may also prevent the devastating brain damage of Alzheimer’s disease, a surprising twist that suggests scientists have a lot more to learn about the root cause of the neurodegenerative condition.

Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the formation of a Scientific Advisory Board comprised of industry leaders in neurology and psychiatry, chaired by James E. Galvin, MD, MPH.

Optimistic about the drug’s efficacy, the company has initiated its submission for accelerated FDA approval.

Approval of aducanumab will herald a new era in Alzheimer’s disease care and research.

The Food and Drug Administration’s controversial June 7 approval of aducanumab (Aduhelm) means that for the first time in 18 years, Alzheimer’s patients have a new treatment option.

The Food and Drug Administration’s approval of Biogen and Eisai’s anti-amyloid antibody aducanumab on June 7 left many questions unanswered, including how to use the drug in clinical practice.

A panel of experts has crafted guidance for clinical use of Aduhelm (aducanumab), the first targeted treatment for Alzheimer’s disease recently granted accelerated approval by the U.S. Food and Drug Administration (FDA).

Not all physicians who treat Alzheimer's disease will prescribe the new Alzheimer's drug aducanumab (Aduhelm) -- major hospital systems like the Cleveland Clinic and Mount Sinai in New York City, for example, won't administer the controversial treatment -- but those who will offer the drug need more information about how to use it, a panel of neuroscientists said.

Appropriate use recommendations for the newly approved Alzheimer disease treatment, aducanumab (Aduhelm; Biogen, Cambridge, MA) have been published in The Journal of Prevention of Alzheimer’s Disease (JPAD).